Original Research
Accepted on 11 May 2026
Systematic Optimization of PD-L1 and CLDN18.2 CAR-T Designs Identifies a Bicistronic Dual-Target, Double-CD3ζ Architecture with Enhanced Antitumor Activity in Gastric Cancer
in Cancer Immunity and Immunotherapy